Peter Hurtubise, DO, Marge Torchia, CRN and Lori Martin, BCHP. CTT, ALT, at Aqua Blue Wellness Center, offer a variety of state-of-the-art health services including thermal imaging, detox therapy, M-pulse saunas, electro-lymphatic therapy (ELT), nutritional IV therapy and massage therapy. They also use supportive oligonucleotide technique (SOT), a treatment for a long list of specific infections, viruses, Lyme disease and cancers. By silencing the genetic code of the infectious agents or cancer cells, this modality is able to kill them, a welcome discovery in light of October’s designation as National Breast Cancer Awareness Month.

Dr. Hurtubise says, “This breakthrough therapy utilizes molecular building blocks (mRNA) that are found naturally in the patient’s own body; it is not technically a drug, since there is no gene manipulation therapy. SOT started at RGCC labs, a medical genetics company in Greece, almost 10 years ago. At that time, it was and is still known as antisense oligodeoxynucleotide therapy (AOT). It is backed by many years of research by European- and American-based companies and universities.”

Nucleotides are the molecules that form the structure of DNA and RNA. Oligonucleotides comprise a supportive sequence of nucleotides rarely no more than 20 amino acids long. The term “antisense” oligodeoxynucleotide means it is designed to bind to its mirror image in the body, blocking its function.

The RGCC antisense molecule is now known as SOT and the treatment is uniquely tailored to each patient’s needs. Apoptosis is another word for programmed cell death. In other words, the SOT molecule has a potent ability to block specific mRNA expression and transcription of a gene which encodes a protein with an anti-apoptotic effect. This explains why a single dose of SOT can turn off the replication cycles of 23 species of Lyme disease and some Lyme disease co-infections and cancer cells. The SOT molecules degrade very slowly and can therefore attack the mRNA in cancer, Lyme and/or viral cells for many months. This is not a genetic therapy.

After the intravenous infusion, the SOT molecules will work around the clock for about six months, during which time they will inhibit the replication of the target infectious agents or cancer cells.

SOT induces rapid apoptosis in circulating tumor cells (CTCs), circulating cancer stem cells (CSCs), primary tumor cells and metastatic tumors. In addition, it is able to cross the blood-brain barrier. As it penetrates into these cells, it will interfere with their ability to replicate. The doctor will recommend a PET/CT, CT or MRI scan prior to the SOT to assess the patient’s cancer for any metastasis to reduce the risk of mild to severe adverse reactions, and to adjust the SOT dosing and timing according to each individual case. Cancer with metastasis could result in tumor lysis syndrome (TLS), which can be life-threatening.